Cell Source IncOTCQB:CLCS
- LAST PRICE0.4255
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.3501/ 25
- Ask / Lots0.5800/ 10
- Open / Previous Close--- / 0.4255
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLCS |
|---|---|---|
| 09:32 ET | 500 | 0.35 |
| 09:39 ET | 100 | 0.46505 |
| 09:51 ET | 200 | 0.58 |
| 10:00 ET | 200 | 0.54496 |
| 10:15 ET | 100 | 0.54532 |
| 10:29 ET | 100 | 0.4225 |
| 10:40 ET | 100 | 0.51904 |
| 01:54 ET | 100 | 0.4505 |
| 02:56 ET | 100 | 0.4255 |
Nov 21, 2024
Cell Source Shares Promising Interim Results From Groundbreaking Veto Cell Clinical Trial, from 8:02AM ET on Thursday Nov 21, 2024 by Dow Jones
8:02AM ET on Thursday Nov 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cell Source Inc | 24.9M | -2.6x | --- |
Cadrenal Therapeutics Inc | 24.9M | -1.9x | --- |
ABPRO Holdings Inc | 25.0M | 21.1x | --- |
Ocean Biomedical Inc | 24.9M | -0.2x | --- |
Athira Pharma Inc | 24.7M | -0.2x | --- |
Lisata Therapeutics Inc | 24.2M | -1.1x | --- |
Company Information
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Contact Information
- Headquarters
- 57 West 57Th Street, Suite 400NEW YORK, NY, United States 10019
- Phone
- 646-612-7554
- Fax
- 646-612-7545
Executives
- Independent Chairman of the Board
- Dennis Brown
- Chief Executive Officer, Chief Financial Officer, Director
- Itamar Shimrat
- Director
- Darlene Soave
- Director
- George Verstraete
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 43.5M |
Cell Source Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.16 |
Book Value | $-0.39 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
